LGALS3 and heart failure: Recent studies have shown that in patients with reduced left ventricular ejection fraction (LVEF) and symptomatic heart failure, Gal-3 levels may serve as a useful biomarker for predicting the development of cardio–renal syndrome (CRS) [78].